依格列汀在肝功能不全患者中的药代动力学与安全性
本研究在韩国轻度或中度肝功能不全患者及匹配健康对照中,单次口服依格列汀5 mg后评估其药代动力学与安全性。轻度肝功能不全者暴露与健康对照相似,中度肝功能不全者暴露增加约40%,但耐受性良好,无需调整剂量。
要点
- 轻度肝功能不全无需调整依格列汀剂量。
- 中度肝功能不全暴露增加约40%,但无需调整剂量。
- 依格列汀在肝功能不全患者中耐受性良好。
核心结论
- 中度肝功能不全患者依格列汀暴露增加约40%,但不太可能影响安全性和有效性,无需调整剂量。
研究设计与样本
- 开放标签、平行组研究,纳入轻度或中度肝功能不全患者及按性别、年龄和体重指数匹配的健康对照,单次口服依格列汀5 mg,采集120小时血样。
主要发现
- 轻度肝功能不全患者与匹配健康对照的Cmax和AUClast几何均值比(GMR)及90%置信区间分别为1.04(0.80, 1.35)和1.01(0.90, 1.14)。
- 中度肝功能不全患者依格列汀Cmax和AUClast的GMR及90%置信区间分别为1.37(1.09, 1.72)和1.44(1.18, 1.75),暴露增加约40%。
- 中度肝功能不全患者M7和M8的代谢比低于匹配健康对照。
- 依格列汀在患者和健康受试者中均耐受良好。
临床怎么用
- 轻度肝功能不全患者使用依格列汀无需调整剂量。
- 中度肝功能不全患者使用依格列汀无需调整剂量,但需关注暴露增加约40%的个体差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Evogliptin is a potent and selective dipeptidyl peptidase-4 inhibitor for glycaemic control in patients with type 2 diabetes mellitus. Since evogliptin is mainly eliminated through hepatic metabolism, we investigated the pharmacokinetics (PKs) and safety characteristics of evogliptin in Korean patients with mild or moderate hepatic impairment. METHODS: An open-label, parallel-group study was conducted in patients with mild or moderate hepatic impairment and healthy control subjects matched to each patient for sex, age and body mass index. A single dose (5 mg) of evogliptin was administered orally, and serial blood samples were collected over 120 h to assess the PK profile of evogliptin and its main metabolites (M7 and M8). RESULTS: Patients with mild hepatic impairment and their matched healthy controls showed similar maximum concentration (Cmax ) and area under the concentration-time curve values from 0 to 120 h (AUClast ); the geometric mean ratio (GMR) and 90% confidence interval (CI) were 1.04 (0.80, 1.35) and 1.01 (0.90, 1.14), respectively. Exposure to evogliptin (Cmax and AUClast ) was increased by about 40% in patients with moderate hepatic impairment-the GMR and 90% CI were 1.37 (1.09, 1.72) and 1.44 (1.18, 1.75), respectively. The metabolic ratios of M7 and M8 were lower in patients with moderate hepatic impairment than in matched healthy controls. Evogliptin was well tolerated by both patients and healthy subjects. CONCLUSION: Although evogliptin exposure was increased in patients with moderate hepatic impairment, the increase is unlikely to affect safety and efficacy adversely, and no dose adjustment is warranted.
引用
- Hong T, Jin BH, Kim CO, et al. Pharmacokinetics and safety of evogliptin in hepatically impaired patients. Br J Clin Pharmacol. 2020. PMID: 33245796. doi:10.1111/bcp.14680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。